|
MX2007009317A
(es)
|
2005-02-03 |
2008-01-30 |
Gen Hospital Corp |
Metodo para tratar cancer resistente a gefitinib.
|
|
US8067175B2
(en)
|
2005-02-11 |
2011-11-29 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for detecting a drug resistant EGFR mutant
|
|
US12366585B2
(en)
|
2006-05-18 |
2025-07-22 |
Caris Mpi, Inc. |
Molecular profiling of tumors
|
|
CN101711284A
(zh)
*
|
2007-01-25 |
2010-05-19 |
达娜-法勃肿瘤研究所 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
|
DK2132229T3
(en)
|
2007-03-01 |
2016-06-20 |
Symphogen As |
Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
|
|
US9340601B2
(en)
|
2007-03-01 |
2016-05-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Splice variants of the EGF receptor
|
|
AR065686A1
(es)
|
2007-03-13 |
2009-06-24 |
Amgen Inc |
Mutaciones de k- ras y b- raf y terapia con anticuerpos anti- egfr
|
|
GB2453173A
(en)
*
|
2007-09-28 |
2009-04-01 |
Dxs Ltd |
Polynucleotide primers
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
TW201002346A
(en)
*
|
2008-04-11 |
2010-01-16 |
Galaxy Biotech Llc |
Combination of HGF inhibitor and EGF inhibitor to treat cancer
|
|
WO2010008744A2
(en)
|
2008-06-17 |
2010-01-21 |
Wyeth |
Antineoplastic combinations containing hki-272 and vinorelbine
|
|
CN102099668B
(zh)
*
|
2008-07-17 |
2013-05-01 |
皇家飞利浦电子股份有限公司 |
纳米孔装置和用于核酸分析的方法
|
|
WO2010022736A2
(en)
|
2008-08-29 |
2010-03-04 |
Symphogen A/S |
Recombinant anti-epidermal growth factor receptor antibody compositions
|
|
CN101445832B
(zh)
*
|
2008-12-23 |
2011-09-14 |
广州益善生物技术有限公司 |
Pik3ca基因突变的检测探针、液相芯片及其检测方法
|
|
IL313131A
(en)
*
|
2009-02-11 |
2024-07-01 |
Caris Mpi Inc |
Molecular characterization of tumors
|
|
US8623604B2
(en)
*
|
2009-09-09 |
2014-01-07 |
Quintiles Transnational Corp. |
Methods for predicting responsiveness of a cancer cell to an anti-IGFR1 antibody by analysis of mutations in PIK3CA
|
|
WO2012005383A2
(ja)
*
|
2010-07-07 |
2012-01-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
正常乳腺上皮細胞からの腫瘍細胞の製造方法
|
|
US20120164641A1
(en)
*
|
2010-12-22 |
2012-06-28 |
Roche Molecular Systems, Inc. |
Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
|
|
WO2012138997A1
(en)
|
2011-04-07 |
2012-10-11 |
Amgen Inc. |
Novel egfr binding proteins
|
|
US9222137B2
(en)
*
|
2011-05-10 |
2015-12-29 |
Trovagene, Inc. |
Method for monitoring minimal residual hairy cell leukemia
|
|
EP2554551A1
(en)
*
|
2011-08-03 |
2013-02-06 |
Fundacio Institut mar d'Investigacions Médiques (IMIM) |
Mutations in the epidermal growth factor receptor gene
|
|
US20140005119A1
(en)
*
|
2012-06-28 |
2014-01-02 |
Case Western Reserve University |
COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
|
|
EP2943578B1
(en)
*
|
2013-01-14 |
2019-04-10 |
National Taiwan University |
Dnazyme for silencing the expression of egfr
|
|
CN103739713B
(zh)
*
|
2013-12-10 |
2016-03-09 |
吴炯 |
一种新型诱导肺瘤细胞凋亡的融合蛋白及其应用
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
WO2015092394A1
(en)
*
|
2013-12-17 |
2015-06-25 |
Kymab Limited |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
GB2521355A
(en)
*
|
2013-12-17 |
2015-06-24 |
Kymab Ltd |
Human targets I
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
CN105779480B
(zh)
*
|
2016-03-24 |
2020-03-20 |
成都康景生物科技有限公司 |
一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用
|
|
CN116903741A
(zh)
|
2016-06-20 |
2023-10-20 |
科马布有限公司 |
特异性结合于pd-l1的抗体或其抗原结合片段及其用途
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
US9980967B1
(en)
|
2017-03-16 |
2018-05-29 |
National Chiao Tung University |
Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
|
|
CN108047308A
(zh)
*
|
2018-02-02 |
2018-05-18 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108047309A
(zh)
*
|
2018-02-07 |
2018-05-18 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108250268A
(zh)
*
|
2018-02-08 |
2018-07-06 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108218960A
(zh)
*
|
2018-03-07 |
2018-06-29 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108409832A
(zh)
*
|
2018-03-07 |
2018-08-17 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108218959A
(zh)
*
|
2018-03-07 |
2018-06-29 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108218961A
(zh)
*
|
2018-03-19 |
2018-06-29 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108440649A
(zh)
*
|
2018-05-31 |
2018-08-24 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108440650A
(zh)
*
|
2018-06-04 |
2018-08-24 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108752424A
(zh)
*
|
2018-06-04 |
2018-11-06 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
CN108440651A
(zh)
*
|
2018-06-08 |
2018-08-24 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
|
WO2020024976A1
(en)
*
|
2018-07-31 |
2020-02-06 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
|
|
CN109485721A
(zh)
*
|
2018-11-23 |
2019-03-19 |
杜学明 |
一种获得肿瘤特异性t细胞受体的方法
|
|
RU2706116C1
(ru)
*
|
2018-12-26 |
2019-11-14 |
Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) |
Способ прогнозирования течения аденокарциномы легкого
|
|
WO2020145754A1
(ko)
*
|
2019-01-11 |
2020-07-16 |
주식회사 진캐스트 |
유전자 변이 특이성이 증가된 dna 중합효소를 이용한 질량분석법
|
|
WO2020145711A1
(ko)
*
|
2019-01-11 |
2020-07-16 |
주식회사 진캐스트 |
Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
|
|
KR102310819B1
(ko)
*
|
2019-01-11 |
2021-10-12 |
주식회사 진캐스트 |
Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
|
|
JOP20210233A1
(ar)
|
2019-02-26 |
2023-01-30 |
Janssen Biotech Inc |
علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met.
|
|
MY208668A
(en)
|
2019-05-14 |
2025-05-23 |
Janssen Biotech Inc |
Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
|
|
CN113993544A
(zh)
*
|
2019-07-24 |
2022-01-28 |
神州细胞工程有限公司 |
用于治疗egfr高表达的癌症的多变剂量方法
|
|
JOP20220184A1
(ar)
|
2020-02-12 |
2023-01-30 |
Janssen Biotech Inc |
علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
|